These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7966729)

  • 21. Construction and evaluation of the immune protection of a recombinant divalent protein composed of the MrpA from MR/P fimbriae and flagellin of Proteus mirabilis strain against urinary tract infection.
    Habibi M; Asadi Karam MR; Bouzari S
    Microb Pathog; 2018 Apr; 117():348-355. PubMed ID: 29452195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses.
    McKay PF; Mann JF; Pattani A; Kett V; Aldon Y; King D; Malcolm RK; Shattock RJ
    J Control Release; 2017 Mar; 249():74-83. PubMed ID: 28115243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosal immunization with a flagellin-adjuvanted Hgp44 vaccine enhances protective immune responses in a murine Porphyromonas gingivalis infection model.
    Puth S; Hong SH; Park MJ; Lee HH; Lee YS; Jeong K; Kang IC; Koh JT; Moon B; Park SC; Rhee JH; Lee SE
    Hum Vaccin Immunother; 2017 Dec; 13(12):2794-2803. PubMed ID: 28604268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in pools of autoantibodies and anti-bacterial antibodies in patients suffering from recurrent infections of the urinary tract and undergoing bacterial immunization treatment.
    Stojanović M; Inić-Kanada A; Popović Z; Zivković I; Dimitrijević L
    Immunol Lett; 2004 Jun; 94(1-2):123-33. PubMed ID: 15234544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urinary antibody response after immunisation with a vaccine against urinary tract infection.
    Kruze D; Holzbecher K; Andrial M; Bossart W
    Urol Res; 1989; 17(6):361-6. PubMed ID: 2623792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial.
    Huttner A; Hatz C; van den Dobbelsteen G; Abbanat D; Hornacek A; Frölich R; Dreyer AM; Martin P; Davies T; Fae K; van den Nieuwenhof I; Thoelen S; de Vallière S; Kuhn A; Bernasconi E; Viereck V; Kavvadias T; Kling K; Ryu G; Hülder T; Gröger S; Scheiner D; Alaimo C; Harbarth S; Poolman J; Fonck VG
    Lancet Infect Dis; 2017 May; 17(5):528-537. PubMed ID: 28238601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis.
    Naber KG; Cho YH; Matsumoto T; Schaeffer AJ
    Int J Antimicrob Agents; 2009 Feb; 33(2):111-9. PubMed ID: 18963856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secretory immune responses in mouse vaginal fluid after pelvic, parenteral or vaginal immunization.
    Thapar MA; Parr EL; Parr MB
    Immunology; 1990 May; 70(1):121-5. PubMed ID: 2354856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of adjuvants on antibody titers in mouse vaginal fluid after intravaginal immunization.
    Thapar MA; Parr EL; Parr MB
    J Reprod Immunol; 1990 Jun; 17(3):207-16. PubMed ID: 2213722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the bacterial vaccine Solco-Urovac® in treatment and prevention of recurrent urinary tract infections of bacterial origin.
    Kochiashvili D; Khuskivadze A; Kochiashvili G; Koberidze G; Kvakhajelidze V
    Georgian Med News; 2014 Jun; (231):11-6. PubMed ID: 25020163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of uterine immunization and oestradiol on specific IgA and IgG antibodies in uterine, vaginal and salivary secretions.
    Wira CR; Sandoe CP
    Immunology; 1989 Sep; 68(1):24-30. PubMed ID: 2807370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
    Hickey DK; Aldwell FE; Beagley KW
    Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies of introital colonization in women with recurrent urinary infections. IV. The role of local vaginal antibodies.
    Stamey TA; Howell JJ
    J Urol; 1976 Apr; 115(4):413-5. PubMed ID: 772238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protection of pigs against genital Chlamydia trachomatis challenge by parenteral or mucosal DNA immunization.
    Schautteet K; De Clercq E; Jönsson Y; Lagae S; Chiers K; Cox E; Vanrompay D
    Vaccine; 2012 Apr; 30(18):2869-81. PubMed ID: 22387629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A quantitative in vivo assay for bacterial adherence to the urethra.
    Uehling DT; Jensen J; Balish E
    J Urol; 1985 Feb; 133(2):316-8. PubMed ID: 3881602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellular and humoral systemic and mucosal immune responses stimulated by an oral polybacterial immunomodulator in patients with chronic urinary tract infections.
    Marinova S; Nenkov P; Markova R; Nikolaeva S; Kostadinova R; Mitov I; Vretenarska M
    Int J Immunopathol Pharmacol; 2005; 18(3):457-473. PubMed ID: 16164822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic immunization with conserved pilus-associated adhesins protects against mucosal infections.
    Palaszynski S; Pinkner J; Leath S; Barren P; Auguste CG; Burlein J; Hultgren S; Langermann S
    Dev Biol Stand; 1998; 92():117-22. PubMed ID: 9554264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses.
    Ugozzoli M; O'Hagan DT; Ott GS
    Immunology; 1998 Apr; 93(4):563-71. PubMed ID: 9659230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of prevalence, immunogenicity and efficacy of FyuA iron receptor in uropathogenic Escherichia coli isolates as a vaccine target against urinary tract infection.
    Habibi M; Asadi Karam MR; Bouzari S
    Microb Pathog; 2017 Sep; 110():477-483. PubMed ID: 28754265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.